At the recently concluded 2023 American Heart Association (AHA) Scientific Sessions 2023, Dr. Chen, Vice President of Chemistry at CureGene, was honored with an invitation to deliver a special presentation entitled "Phase I Result of a Novel Antiplatelet Drug CG-0255 That is Fast-Acting, Long Lasting and Available for Either IV or Oral Administration" on November 12, 2023. As a Featured Science speaker at this prestigious event in the cardiovascular domain, Dr. Chen  shared insights from Phase I trials of CG-0255 administered intravenously.

CG-0255 is a revolutionary antiplatelet drug with truly unique and innovative design, it has been developed in two formulations: intravenous injection and oral tablets. It is currently undergoing clinical development for indications such as acute coronary syndrome, recent myocardial infarction, recent stroke, and peripheral arterial disease to address the shortcomings of existing treatment options, unmet clinical needs, and to provide better antiplatelet solutions for all patients. CG-0255 has rapid onset of action, good safety profile, and shows minimal individual variations, overcoming widely present resistant issue with current treatment. CG-0255 also has little drug-drug interactions. It has the potential to become the best-in-class P2Y12antagonist antiplatelet drug and fully meet the clinical needs in various medication scenarios.